Skip to content
10-Q

Quarterly Report

OPIANT PHARMACEUTICALS, INC.

0001385508-22-000054

← back to feed
Filed
May 10, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 9, 2022 5.09M sh
Shares Diluted Q1 2022 · Mar 31, 2022 5.02M sh
Shares Diluted Q1 2022 · Mar 31, 2021 4.28M sh
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$2.1M
Operating Cash Flow Q1 2022 · Mar 31, 2021 $1.71M
Long Term Debt Q1 2022 · Mar 31, 2022 $13.7M
Long Term Debt Q1 2022 · Dec 31, 2021 $16.1M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $48.33M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $37.85M
Stockholders Equity Q1 2022 · Mar 31, 2022 $39.26M
Stockholders Equity Q1 2022 · Dec 31, 2021 $46.84M
Stockholders Equity Q1 2022 · Mar 31, 2021 $33.99M
Stockholders Equity Q1 2022 · Dec 31, 2020 $35.49M
Current Liabilities Q1 2022 · Mar 31, 2022 $6.79M
Current Liabilities Q1 2022 · Dec 31, 2021 $6.85M
Total Liabilities Q1 2022 · Mar 31, 2022 $21.06M
Total Liabilities Q1 2022 · Dec 31, 2021 $23.59M
Current Assets Q1 2022 · Mar 31, 2022 $59.16M
Current Assets Q1 2022 · Dec 31, 2021 $69.16M
Total Assets Q1 2022 · Mar 31, 2022 $60.32M
Total Assets Q1 2022 · Dec 31, 2021 $70.43M
Eps Diluted Q1 2022 · Mar 31, 2022 −$2.43
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.66
Eps Basic Q1 2022 · Mar 31, 2022 −$2.43
Eps Basic Q1 2022 · Mar 31, 2021 −$0.66
Sga Expense Q1 2022 · Mar 31, 2022 $4.33M
Sga Expense Q1 2022 · Mar 31, 2021 $2.65M
Rd Expense Q1 2022 · Mar 31, 2022 $8.82M
Rd Expense Q1 2022 · Mar 31, 2021 $4.09M
Net Income Q1 2022 · Mar 31, 2022 −$12.19M
Net Income Q1 2022 · Mar 31, 2021 −$2.84M
Operating Income Q1 2022 · Mar 31, 2022 −$11.79M
Operating Income Q1 2022 · Mar 31, 2021 −$2.32M
Revenue Q1 2022 · Mar 31, 2022 $4.47M
Revenue Q1 2022 · Mar 31, 2021 $6.39M